NIKKEI 225
38,329.39 +777.23 (+2.07%) HANG SENG
17,110.72 +281.79 (+1.67%) CRUDE OIL
83.34 -0.02 (-0.02%) GOLD FUTURES
2,334.80 -7.30 (-0.31%) DOW
38,503.69 +263.71 (+0.69%) Bitcoin GBP
53,511.52 -104.18 (-0.19%)
Regeneron Pharmaceuticals, Inc. (0R2M.L)
| Previous close | 907.50 |
| Open | 0.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 0.00 - 0.00 |
| 52-week range | |
| Volume | |
| Avg. volume | 1,962 |
| Market cap | 1.012B |
| Beta (5Y monthly) | 0.14 |
| PE ratio (TTM) | 0.13 |
| EPS (TTM) | 70.31 |
| Earnings date | 02 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireRegeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT)
Oral presentations include updated results from clinical study of otoferlin gene therapy DB-OTO demonstrating restoration in children with profound genetic hearing loss Additional presentations cover progress in novel genetic medicine delivery systems and immune response modulation TARRYTOWN, N.Y., April 22, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that new and updated data across its genetic medicines portfolio will be presented at the American Soc
ZacksAgenus (AGEN) Soars 6.8%: Is Further Upside Left in the Stock?
Agenus (AGEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Simply Wall St.Regeneron Pharmaceuticals Insiders Sell US$26m Of Stock, Possibly Signalling Caution
Over the past year, many Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) insiders sold a significant stake in the...
